[{"orgOrder":0,"company":"Rachel G. Greenberg, MD, MB, MHS","sponsor":"The Emmes Company, LLC | Gansu Provincial Maternal and Child Health Care Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Guanfacine","moa":"Adrenergic receptor alpha-2","graph1":"Genetic Disease","graph2":"Phase II","graph3":"Rachel G. Greenberg, MD, MB, MHS","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Rachel G. Greenberg, MD, MB, MHS \/ The Emmes Company, LLC | Gansu Provincial Maternal and Child Health Care Hospital","highestDevelopmentStatusID":"8","companyTruncated":"Rachel G. Greenberg, MD, MB, MHS \/ The Emmes Company, LLC | Gansu Provincial Maternal and Child Health Care Hospital"}]

Find Clinical Drug Pipeline Developments & Deals for Guanfacine HCl

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Rachel G. Greenberg, MD, MB, MHS

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Rachel G. Greenberg, MD, MB, MHS

                          Country arrow
                          Aus. Peptide Conference
                          Not Confirmed

                          Lead Product(s) : Guanfacine

                          Therapeutic Area : Genetic Disease

                          Study Phase : Phase II

                          Sponsor : The Emmes Company, LLC | Gansu Provincial Maternal and Child Health Care Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          Details : Guanfacine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Down Syndrome.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          September 18, 2023

                          Lead Product(s) : Guanfacine

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase II

                          Sponsor : The Emmes Company, LLC | Gansu Provincial Maternal and Child Health Care Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank